Header Logo

Connection

FASIHA KANWAL to Humans

Back to Details
This is a "connection" page, showing publications FASIHA KANWAL has written about Humans.
FASIHA KANWAL
Connection Strength
3.024
Humans
  1. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.026
  2. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.026
  3. Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024 Jul 25; 391(4):371-372.
    View in: PubMed
    Score: 0.025
  4. Unseen foe: The financial toxicity of liver transplantation. Liver Transpl. 2024 Sep 01; 30(9):873-874.
    View in: PubMed
    Score: 0.025
  5. Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 May; 80(5):e218-e219.
    View in: PubMed
    Score: 0.024
  6. The Impact of Race on Pancreatic Cancer Treatment and Survival in the Nationwide Veterans Affairs Healthcare System. Pancreas. 2024 Jan 01; 53(1):e27-e33.
    View in: PubMed
    Score: 0.024
  7. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024 05 01; 79(5):1212-1219.
    View in: PubMed
    Score: 0.024
  8. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.024
  9. Cost of Care for Patients With Cirrhosis. Am J Gastroenterol. 2024 03 01; 119(3):497-504.
    View in: PubMed
    Score: 0.024
  10. Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System. Dig Dis Sci. 2023 09; 68(9):3634-3643.
    View in: PubMed
    Score: 0.024
  11. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.023
  12. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.023
  13. Actionable Solutions to Achieve Health Equity in Chronic Liver Disease. Clin Gastroenterol Hepatol. 2023 07; 21(8):1992-2000.
    View in: PubMed
    Score: 0.023
  14. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.023
  15. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.022
  16. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.022
  17. Risk of Hepatocellular Carcinoma in Patients with Various HFE Genotypes. Dig Dis Sci. 2023 01; 68(1):312-322.
    View in: PubMed
    Score: 0.022
  18. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.022
  19. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022 09; 76(3):819-853.
    View in: PubMed
    Score: 0.022
  20. Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology. 2022 09; 76(3):546-548.
    View in: PubMed
    Score: 0.022
  21. Farewell From the Outgoing Clinical Gastroenterology and Hepatology Board of Editors. Clin Gastroenterol Hepatol. 2022 06; 20(6):1197-1200.
    View in: PubMed
    Score: 0.021
  22. Cirrhosis Quality Collaborative. Clin Gastroenterol Hepatol. 2022 05; 20(5):970-972.
    View in: PubMed
    Score: 0.021
  23. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.021
  24. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.021
  25. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
    View in: PubMed
    Score: 0.021
  26. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.021
  27. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021 11; 161(5):1657-1669.
    View in: PubMed
    Score: 0.021
  28. Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. Transpl Int. 2021 Oct; 34(10):1971-1983.
    View in: PubMed
    Score: 0.021
  29. NAFLD and HCC: Time to Bridge the Gap. Hepatology. 2021 11; 74(5):2336-2338.
    View in: PubMed
    Score: 0.021
  30. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412.
    View in: PubMed
    Score: 0.021
  31. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172.
    View in: PubMed
    Score: 0.021
  32. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.021
  33. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.020
  34. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Intern Med. 2021 07 01; 181(7):949-959.
    View in: PubMed
    Score: 0.020
  35. Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. Gastroenterology. 2021 07; 161(1):333-335.
    View in: PubMed
    Score: 0.020
  36. On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol. 2021 05; 19(5):865-870.
    View in: PubMed
    Score: 0.020
  37. Unconscious Bias in Peer Review. Clin Gastroenterol Hepatol. 2021 03; 19(3):419-420.
    View in: PubMed
    Score: 0.020
  38. Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure". J Hepatol. 2021 02; 74(2):477.
    View in: PubMed
    Score: 0.020
  39. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
    View in: PubMed
    Score: 0.020
  40. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.019
  41. Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure". J Hepatol. 2020 12; 73(6):1579-1580.
    View in: PubMed
    Score: 0.019
  42. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
    View in: PubMed
    Score: 0.019
  43. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
    View in: PubMed
    Score: 0.019
  44. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.019
  45. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.019
  46. Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. Clin Gastroenterol Hepatol. 2020 07; 18(8):1858-1866.e6.
    View in: PubMed
    Score: 0.018
  47. Covering the Year in CGH: 2019. Clin Gastroenterol Hepatol. 2020 01; 18(1):3-10.
    View in: PubMed
    Score: 0.018
  48. The HCV Treatment Cascade: Race Is a Factor to Consider. J Gen Intern Med. 2019 10; 34(10):1949-1951.
    View in: PubMed
    Score: 0.018
  49. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.018
  50. Integrated Model for Patient-Centered Advanced Liver Disease Care. Clin Gastroenterol Hepatol. 2020 05; 18(5):1015-1024.
    View in: PubMed
    Score: 0.018
  51. Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure". J Hepatol. 2019 09; 71(3):638-639.
    View in: PubMed
    Score: 0.018
  52. Quality of Care Indicators in Patients with Acute Pancreatitis. Dig Dis Sci. 2019 09; 64(9):2514-2526.
    View in: PubMed
    Score: 0.018
  53. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019 07; 50(1):66-74.
    View in: PubMed
    Score: 0.018
  54. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. JAMA Netw Open. 2019 05 03; 2(5):e193613.
    View in: PubMed
    Score: 0.018
  55. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
    View in: PubMed
    Score: 0.018
  56. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019 07; 157(1):54-64.
    View in: PubMed
    Score: 0.018
  57. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. J Viral Hepat. 2019 05; 26(5):596-602.
    View in: PubMed
    Score: 0.017
  58. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019 06; 156(8):2149-2157.
    View in: PubMed
    Score: 0.017
  59. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019 04; 69(4):1787-1797.
    View in: PubMed
    Score: 0.017
  60. Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?" J Hepatol. 2019 06; 70(6):1301-1302.
    View in: PubMed
    Score: 0.017
  61. A Roadmap for Value-Based Payment Models Among Patients With Cirrhosis. Hepatology. 2019 03; 69(3):1300-1305.
    View in: PubMed
    Score: 0.017
  62. Nutrition in Alcoholic Liver Disease: An Update. Clin Liver Dis. 2019 02; 23(1):99-114.
    View in: PubMed
    Score: 0.017
  63. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.017
  64. Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. Am J Gastroenterol. 2019 01; 114(1):98-106.
    View in: PubMed
    Score: 0.017
  65. Project ECHO: The Specialist Will See You Now. Hepatology. 2018 12; 68(6):2066-2068.
    View in: PubMed
    Score: 0.017
  66. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.017
  67. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.017
  68. Implementation of a Population-Based Cirrhosis Identification and Management System. Clin Gastroenterol Hepatol. 2018 08; 16(8):1182-1186.e2.
    View in: PubMed
    Score: 0.016
  69. Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. Gastroenterology. 2018 09; 155(3):719-729.e4.
    View in: PubMed
    Score: 0.016
  70. Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clin Gastroenterol Hepatol. 2018 10; 16(10):1677-1678.
    View in: PubMed
    Score: 0.016
  71. Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. Clin Gastroenterol Hepatol. 2018 04; 16(4):459-461.
    View in: PubMed
    Score: 0.016
  72. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.016
  73. Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017 12; 15(12):1823-1827.
    View in: PubMed
    Score: 0.016
  74. A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus. Health Serv Res. 2018 08; 53(4):2547-2566.
    View in: PubMed
    Score: 0.016
  75. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.016
  76. Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Dig Dis Sci. 2017 10; 62(10):2713-2718.
    View in: PubMed
    Score: 0.016
  77. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.016
  78. Reply to: "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection". J Hepatol. 2017 10; 67(4):886-887.
    View in: PubMed
    Score: 0.015
  79. Reply to: "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients". J Hepatol. 2017 10; 67(4):884-885.
    View in: PubMed
    Score: 0.015
  80. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.015
  81. Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. Am J Gastroenterol. 2017 Aug; 112(8):1287-1297.
    View in: PubMed
    Score: 0.015
  82. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
    View in: PubMed
    Score: 0.015
  83. Hepatitis C and Risk of Nonhepatic Malignancies. Clin Liver Dis. 2017 08; 21(3):543-554.
    View in: PubMed
    Score: 0.015
  84. The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Dig Dis Sci. 2017 May; 62(5):1180-1185.
    View in: PubMed
    Score: 0.015
  85. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
    View in: PubMed
    Score: 0.015
  86. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):122-132.
    View in: PubMed
    Score: 0.015
  87. The Top Five Reasons You Should Publish in Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017 02; 15(2):164-165.
    View in: PubMed
    Score: 0.015
  88. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.015
  89. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.015
  90. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. Dig Dis Sci. 2017 01; 62(1):76-83.
    View in: PubMed
    Score: 0.015
  91. Communication and trust: Critically important to eliminate disparities in liver transplantation. Liver Transpl. 2016 07; 22(7):881-3.
    View in: PubMed
    Score: 0.014
  92. Collaborative Care for Depression in Chronic Hepatitis C Clinics. Psychiatr Serv. 2016 10 01; 67(10):1076-1082.
    View in: PubMed
    Score: 0.014
  93. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016 11; 64(5):1442-1450.
    View in: PubMed
    Score: 0.014
  94. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis. 2016 08 01; 63(3):291-9.
    View in: PubMed
    Score: 0.014
  95. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
    View in: PubMed
    Score: 0.014
  96. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.014
  97. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
    View in: PubMed
    Score: 0.014
  98. Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Dig Dis Sci. 2016 06; 61(6):1714-20.
    View in: PubMed
    Score: 0.014
  99. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol. 2015 Oct 01; 15:124.
    View in: PubMed
    Score: 0.014
  100. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):301-8.e1-2.
    View in: PubMed
    Score: 0.014
  101. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver?Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):191-202.e1-4; quiz e20.
    View in: PubMed
    Score: 0.014
  102. Pay for Performance in Chronic Liver Disease. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2042-7.
    View in: PubMed
    Score: 0.013
  103. Why We Should Be Willing to Pay for Hepatitis C Treatment. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1711-3.
    View in: PubMed
    Score: 0.013
  104. Decreasing mortality in patients hospitalized with cirrhosis. Gastroenterology. 2015 May; 148(5):897-900.
    View in: PubMed
    Score: 0.013
  105. Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Dig Dis Sci. 2015 Jul; 60(7):2030-7.
    View in: PubMed
    Score: 0.013
  106. Surveillance for hepatocellular carcinoma: can we focus on the mission? Clin Gastroenterol Hepatol. 2015 Apr; 13(4):805-7.
    View in: PubMed
    Score: 0.013
  107. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.013
  108. Improving quality of health care for patients with cirrhosis. Gastroenterology. 2014 Dec; 147(6):1204-7.
    View in: PubMed
    Score: 0.013
  109. Primary prophylaxis of variceal bleeding. Gastroenterol Clin North Am. 2014 Dec; 43(4):783-94.
    View in: PubMed
    Score: 0.013
  110. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014 Oct; 40(8):949-54.
    View in: PubMed
    Score: 0.013
  111. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014 Nov; 60(5):1767-75.
    View in: PubMed
    Score: 0.013
  112. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.013
  113. The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
    View in: PubMed
    Score: 0.013
  114. Obesity and hepatocellular carcinoma: hype and reality. Hepatology. 2014 Sep; 60(3):779-81.
    View in: PubMed
    Score: 0.013
  115. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015 Jan; 110(1):10-4.
    View in: PubMed
    Score: 0.013
  116. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.012
  117. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1381-3.
    View in: PubMed
    Score: 0.012
  118. The end of hepatitis C. Clin Gastroenterol Hepatol. 2014 Apr; 12(4):533-6.
    View in: PubMed
    Score: 0.012
  119. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):327-333.e1.
    View in: PubMed
    Score: 0.012
  120. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci. 2014 Feb; 59(2):273-81.
    View in: PubMed
    Score: 0.012
  121. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
    View in: PubMed
    Score: 0.012
  122. Patient-reported outcomes of cirrhosis. Clin Gastroenterol Hepatol. 2013 Sep; 11(9):1043-5.
    View in: PubMed
    Score: 0.012
  123. Coordinating care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2013 Jul; 11(7):859-61.
    View in: PubMed
    Score: 0.012
  124. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology. 2013 Mar; 144(3):478-81.
    View in: PubMed
    Score: 0.011
  125. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):200-3.
    View in: PubMed
    Score: 0.011
  126. a-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):441-3.
    View in: PubMed
    Score: 0.011
  127. "Systematic Reviews and Meta-analyses" in Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1184-6.
    View in: PubMed
    Score: 0.011
  128. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
    View in: PubMed
    Score: 0.011
  129. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012 Oct; 107(10):1512-21.
    View in: PubMed
    Score: 0.011
  130. Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network. Aliment Pharmacol Ther. 2012 Aug; 36(3):257-65.
    View in: PubMed
    Score: 0.011
  131. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012 Jul; 143(1):70-7.
    View in: PubMed
    Score: 0.011
  132. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012 Jan 01; 54(1):96-104.
    View in: PubMed
    Score: 0.011
  133. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
    View in: PubMed
    Score: 0.010
  134. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med. 2010 Aug 17; 153(4):231-9.
    View in: PubMed
    Score: 0.010
  135. Measuring quality of care in patients with nonvariceal upper gastrointestinal hemorrhage: development of an explicit quality indicator set. Am J Gastroenterol. 2010 Aug; 105(8):1710-8.
    View in: PubMed
    Score: 0.010
  136. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):709-17.
    View in: PubMed
    Score: 0.009
  137. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):79-84.
    View in: PubMed
    Score: 0.009
  138. Protecting the stomach from the "toxins" of NSAIDS and anti-platelet agents. Mo Med. 2009 Sep-Oct; 106(5):343-5.
    View in: PubMed
    Score: 0.009
  139. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009 Jul; 7(7):793-9.
    View in: PubMed
    Score: 0.009
  140. Hepatocellular cancer care: cost is important but only one factor of disease burden. J Hepatol. 2009 Jan; 50(1):10-2.
    View in: PubMed
    Score: 0.008
  141. Prospective validation of the short form liver disease quality of life instrument. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1088-101.
    View in: PubMed
    Score: 0.008
  142. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007 Dec; 46(6):1741-9.
    View in: PubMed
    Score: 0.008
  143. Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. Hepatology. 2007 Jul; 46(1):113-21.
    View in: PubMed
    Score: 0.008
  144. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006 Sep; 101(9):2076-89.
    View in: PubMed
    Score: 0.007
  145. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006 May; 119(5):448.e27-36.
    View in: PubMed
    Score: 0.007
  146. Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample. Am J Gastroenterol. 2005 Sep; 100(9):1984-94.
    View in: PubMed
    Score: 0.007
  147. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005 May 17; 142(10):821-31.
    View in: PubMed
    Score: 0.007
  148. A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol. BMC Health Serv Res. 2025 May 06; 25(1):645.
    View in: PubMed
    Score: 0.007
  149. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005 Apr; 41(4):790-800.
    View in: PubMed
    Score: 0.007
  150. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
    View in: PubMed
    Score: 0.007
  151. A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):169-77.
    View in: PubMed
    Score: 0.007
  152. Prevalence and Outcomes of Emergency Presentations of Colorectal Cancer in Veterans Affairs Health Care System. Dig Dis Sci. 2025 Jan; 70(1):177-190.
    View in: PubMed
    Score: 0.006
  153. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.006
  154. National Liver Cancer Screening Trial (TRACER) study protocol. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.006
  155. Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004 Sep; 99(9):1726-32.
    View in: PubMed
    Score: 0.006
  156. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
    View in: PubMed
    Score: 0.006
  157. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.006
  158. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.006
  159. Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study. Am J Gastroenterol. 2024 Nov 01; 119(11):2251-2258.
    View in: PubMed
    Score: 0.006
  160. Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients. JAMA Netw Open. 2024 04 01; 7(4):e248755.
    View in: PubMed
    Score: 0.006
  161. Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2024 09 01; 80(3):742-753.
    View in: PubMed
    Score: 0.006
  162. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement. Hepatol Commun. 2024 02 01; 8(2).
    View in: PubMed
    Score: 0.006
  163. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
    View in: PubMed
    Score: 0.006
  164. A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl. 2003 Dec; 9(12):1312-9.
    View in: PubMed
    Score: 0.006
  165. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024 Mar 01; 79(3):E93-E94.
    View in: PubMed
    Score: 0.006
  166. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023 Dec; 20(12):864-884.
    View in: PubMed
    Score: 0.006
  167. A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients. Am J Gastroenterol. 2024 03 01; 119(3):505-511.
    View in: PubMed
    Score: 0.006
  168. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol. 2023 Dec; 20(12):797-809.
    View in: PubMed
    Score: 0.006
  169. Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review. Hepatol Commun. 2023 08 01; 7(8).
    View in: PubMed
    Score: 0.006
  170. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 12 01; 78(6):1966-1986.
    View in: PubMed
    Score: 0.006
  171. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 12; 79(6):1542-1556.
    View in: PubMed
    Score: 0.006
  172. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb; 29(1):101133.
    View in: PubMed
    Score: 0.006
  173. Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes. Cancer Med. 2023 07; 12(14):15011-15025.
    View in: PubMed
    Score: 0.006
  174. The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol. 2023 09; 79(3):717-727.
    View in: PubMed
    Score: 0.006
  175. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clin Gastroenterol Hepatol. 2024 01; 22(1):91-101.e6.
    View in: PubMed
    Score: 0.006
  176. Targets and study design for symptom-focused trials aimed at patients with cirrhosis: An expert consensus. Hepatol Commun. 2023 06 01; 7(6).
    View in: PubMed
    Score: 0.006
  177. Survival following liver transplantation for hepatocellular carcinoma after implementation of MMaT-3 policy. Liver Transpl. 2023 10 01; 29(10):1138-1142.
    View in: PubMed
    Score: 0.006
  178. Transplanting hepatitis B surface antigen-positive livers in the United States: Outcomes and opportunities. Am J Transplant. 2023 08; 23(8):1221-1226.
    View in: PubMed
    Score: 0.006
  179. Alcohol-Associated Liver Disease Mortality Rates by Race Before and During the COVID-19 Pandemic in the US. JAMA Health Forum. 2023 04 07; 4(4):e230527.
    View in: PubMed
    Score: 0.006
  180. The Association between Caffeine Intake and the Colonic Mucosa-Associated Gut Microbiota in Humans-A Preliminary Investigation. Nutrients. 2023 Apr 03; 15(7).
    View in: PubMed
    Score: 0.006
  181. Major stigmata of recent hemorrhage on rectal ulcers in patients with severe hematochezia: Endoscopic diagnosis, treatment, and outcomes. Gastrointest Endosc. 2003 Apr; 57(4):462-8.
    View in: PubMed
    Score: 0.006
  182. Posttransplant outcomes for alcohol-associated liver disease during the COVID-19 pandemic. Liver Transpl. 2023 07 01; 29(7):777-780.
    View in: PubMed
    Score: 0.006
  183. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.006
  184. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023 02 18; 76(4):592-599.
    View in: PubMed
    Score: 0.006
  185. Telehealth interventions in patients with chronic liver diseases: A systematic review. Hepatology. 2023 07 01; 78(1):179-194.
    View in: PubMed
    Score: 0.006
  186. Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Ann Hepatol. 2023 Mar-Apr; 28(2):100899.
    View in: PubMed
    Score: 0.006
  187. A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023 02; 57(3):304-312.
    View in: PubMed
    Score: 0.006
  188. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.006
  189. Is Liver Transplant Justified at Any MELD Score? Transplantation. 2023 03 01; 107(3):680-692.
    View in: PubMed
    Score: 0.006
  190. The Predictive Performance of Contemporary Guideline Recommendations for Helicobacter pylori Testing in a United States Population. Clin Gastroenterol Hepatol. 2023 Jul; 21(7):1771-1780.
    View in: PubMed
    Score: 0.006
  191. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.006
  192. Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review. Liver Transpl. 2022 12; 28(12):1865-1875.
    View in: PubMed
    Score: 0.006
  193. Two mental models of integrated care for advanced liver disease: qualitative study of multidisciplinary health professionals. BMJ Open. 2022 09 05; 12(9):e062836.
    View in: PubMed
    Score: 0.006
  194. Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. Liver Transpl. 2023 01 01; 29(1):15-25.
    View in: PubMed
    Score: 0.005
  195. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
    View in: PubMed
    Score: 0.005
  196. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
    View in: PubMed
    Score: 0.005
  197. Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. JAMA Netw Open. 2022 07 01; 5(7):e2223504.
    View in: PubMed
    Score: 0.005
  198. Dietary Fatty Acid Intake and the Colonic Gut Microbiota in Humans. Nutrients. 2022 Jun 29; 14(13).
    View in: PubMed
    Score: 0.005
  199. The chosen and the unchosen: How eligibility for liver transplant influences the lived experiences of patients with advanced liver disease. Soc Sci Med. 2022 07; 305:115113.
    View in: PubMed
    Score: 0.005
  200. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep. 2022 04 05; 12(1):5695.
    View in: PubMed
    Score: 0.005
  201. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clin Gastroenterol Hepatol. 2023 05; 21(5):1362-1364.e1.
    View in: PubMed
    Score: 0.005
  202. Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. Clin Transplant. 2022 06; 36(6):e14646.
    View in: PubMed
    Score: 0.005
  203. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.005
  204. Prognosis conversations in advanced liver disease: A qualitative interview study with health professionals and patients. PLoS One. 2022; 17(2):e0263874.
    View in: PubMed
    Score: 0.005
  205. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol. 2022 07; 77(1):55-62.
    View in: PubMed
    Score: 0.005
  206. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
    View in: PubMed
    Score: 0.005
  207. Why Do Small Intraductal Papillary Mucinous Neoplasms Create Such a Huge Management Challenge?: How International Classification of Diseases Codes Have Failed Us. Pancreas. 2022 02 01; 51(2):e13-e15.
    View in: PubMed
    Score: 0.005
  208. Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 07; 76(1):251-274.
    View in: PubMed
    Score: 0.005
  209. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 05; 75(5):1289-1299.
    View in: PubMed
    Score: 0.005
  210. Marginal allografts in liver transplantation have a limited impact on length of stay. Clin Transplant. 2022 03; 36(3):e14544.
    View in: PubMed
    Score: 0.005
  211. Clinical Factors Associated With Lack of Serological Response to SARS-CoV-2 Messenger RNA Vaccine in Liver Transplantation Recipients. Liver Transpl. 2022 01; 28(1):123-126.
    View in: PubMed
    Score: 0.005
  212. Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999-2018. Clin Gastroenterol Hepatol. 2023 01; 21(1):223-225.e3.
    View in: PubMed
    Score: 0.005
  213. Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS-CoV-2 Infection. Liver Transpl. 2022 01; 28(1):127-130.
    View in: PubMed
    Score: 0.005
  214. Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microb Ecol. 2022 Apr; 83(3):811-821.
    View in: PubMed
    Score: 0.005
  215. Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology. 2021 07; 74(1):474-482.
    View in: PubMed
    Score: 0.005
  216. Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. Lancet Gastroenterol Hepatol. 2021 06; 6(6):422-424.
    View in: PubMed
    Score: 0.005
  217. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemp Clin Trials. 2021 05; 104:106367.
    View in: PubMed
    Score: 0.005
  218. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020 11 02; 3(11):e2021173.
    View in: PubMed
    Score: 0.005
  219. Early Impact of COVID-19 on Solid Organ Transplantation in the United States. Transplantation. 2020 11; 104(11):2221-2224.
    View in: PubMed
    Score: 0.005
  220. Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. Dig Dis Sci. 2021 09; 66(9):2981-2991.
    View in: PubMed
    Score: 0.005
  221. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol. 2022 01; 20(1):9-18.
    View in: PubMed
    Score: 0.005
  222. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6.
    View in: PubMed
    Score: 0.005
  223. Aggressive utilization of liver allografts: Improved outcomes over time. Clin Transplant. 2020 07; 34(7):e13860.
    View in: PubMed
    Score: 0.005
  224. Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. Transpl Int. 2020 08; 33(8):925-935.
    View in: PubMed
    Score: 0.005
  225. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.005
  226. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.005
  227. A learning curve in using orphan liver allografts for transplantation. Clin Transplant. 2020 04; 34(4):e13821.
    View in: PubMed
    Score: 0.005
  228. Measuring the Quality of Palliative Care for Patients with End-Stage Liver Disease. Dig Dis Sci. 2020 09; 65(9):2562-2570.
    View in: PubMed
    Score: 0.005
  229. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
    View in: PubMed
    Score: 0.005
  230. Dietary quality and the colonic mucosa-associated gut microbiome in humans. Am J Clin Nutr. 2019 09 01; 110(3):701-712.
    View in: PubMed
    Score: 0.004
  231. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019 06 11; 9(6):e026726.
    View in: PubMed
    Score: 0.004
  232. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.004
  233. Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients. 2019 Mar 13; 11(3).
    View in: PubMed
    Score: 0.004
  234. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
    View in: PubMed
    Score: 0.004
  235. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 04; 70(4):639-647.
    View in: PubMed
    Score: 0.004
  236. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.
    View in: PubMed
    Score: 0.004
  237. Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol. 2019 03; 17(4):739-747.e8.
    View in: PubMed
    Score: 0.004
  238. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology. 2018 07; 68(1):7-9.
    View in: PubMed
    Score: 0.004
  239. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology. 2018 06; 67(6):2085-2095.
    View in: PubMed
    Score: 0.004
  240. Patient-reported outcomes in cirrhosis: A scoping review of the literature. Hepatology. 2018 06; 67(6):2375-2383.
    View in: PubMed
    Score: 0.004
  241. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol. 2018 07; 16(7):992-1002.e6.
    View in: PubMed
    Score: 0.004
  242. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci. 2018 05; 63(5):1173-1181.
    View in: PubMed
    Score: 0.004
  243. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther. 2018 Apr; 47(7):1023-1031.
    View in: PubMed
    Score: 0.004
  244. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
    View in: PubMed
    Score: 0.004
  245. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.004
  246. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):115-122.e10.
    View in: PubMed
    Score: 0.004
  247. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017 03; 65(3):777-788.
    View in: PubMed
    Score: 0.004
  248. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci. 2017 02; 62(2):526-533.
    View in: PubMed
    Score: 0.004
  249. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.004
  250. Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis. Dig Dis Sci. 2017 01; 62(1):84-92.
    View in: PubMed
    Score: 0.004
  251. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2017 02; 15(2):310-312.
    View in: PubMed
    Score: 0.004
  252. Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clin Gastroenterol Hepatol. 2016 12; 14(12):1678-1680.
    View in: PubMed
    Score: 0.004
  253. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol. 2017 02; 15(2):273-281.e1.
    View in: PubMed
    Score: 0.004
  254. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
    View in: PubMed
    Score: 0.004
  255. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.004
  256. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
    View in: PubMed
    Score: 0.003
  257. The Art and Science of Managing Liver Disease. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2029-30.
    View in: PubMed
    Score: 0.003
  258. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan; 14(1):124-31.e1.
    View in: PubMed
    Score: 0.003
  259. Response to Li et al. Am J Gastroenterol. 2015 May; 110(5):774.
    View in: PubMed
    Score: 0.003
  260. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015 Mar 17; 162(6):397-406.
    View in: PubMed
    Score: 0.003
  261. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1521-31.e3.
    View in: PubMed
    Score: 0.003
  262. Use of Hy's Law, R criteria, and nR criteria to predict acute liver failure or transplantation in patients with drug-induced liver injury. Gastroenterology. 2015 Feb; 148(2):452.
    View in: PubMed
    Score: 0.003
  263. New diagnosis of chronic pancreatitis: risk of missing an underlying pancreatic cancer. Am J Gastroenterol. 2014 Nov; 109(11):1824-30.
    View in: PubMed
    Score: 0.003
  264. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):594-601.e1.
    View in: PubMed
    Score: 0.003
  265. Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci. 2014 Jul; 59(7):1586-93.
    View in: PubMed
    Score: 0.003
  266. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014 Mar; 39(5):518-31.
    View in: PubMed
    Score: 0.003
  267. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.003
  268. Increased risk of pancreatic adenocarcinoma after acute pancreatitis. Clin Gastroenterol Hepatol. 2014 Jul; 12(7):1143-1150.e1.
    View in: PubMed
    Score: 0.003
  269. The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther. 2013 Jul; 38(1):28-37.
    View in: PubMed
    Score: 0.003
  270. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.003
  271. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1342-1359.e2.
    View in: PubMed
    Score: 0.003
  272. National patterns and predictors of liver biopsy use for management of hepatitis C. J Hepatol. 2012 Aug; 57(2):252-9.
    View in: PubMed
    Score: 0.003
  273. Screening high risk individuals for hepatitis B: physician knowledge, attitudes, and beliefs. Dig Dis Sci. 2011 Dec; 56(12):3471-87.
    View in: PubMed
    Score: 0.003
  274. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012 Feb; 56(2):320-5.
    View in: PubMed
    Score: 0.003
  275. Impact of nasogastric lavage on outcomes in acute GI bleeding. Gastrointest Endosc. 2011 Nov; 74(5):971-80.
    View in: PubMed
    Score: 0.003
  276. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011 Mar; 53(3):737-45.
    View in: PubMed
    Score: 0.002
  277. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.002
  278. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology. 2011 Jan; 53(1):42-52.
    View in: PubMed
    Score: 0.002
  279. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
    View in: PubMed
    Score: 0.002
  280. Transforming strategies for the prevention of chronic HBV and HCV infections. J Fam Pract. 2010 Apr; 59(4 Suppl):S23-8.
    View in: PubMed
    Score: 0.002
  281. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009 Jun; 49(6):1904-12.
    View in: PubMed
    Score: 0.002
  282. Viral RNA testing in hepatitis C antibody-positive veterans. Am J Prev Med. 2009 Mar; 36(3):235-8.
    View in: PubMed
    Score: 0.002
  283. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1078-87.
    View in: PubMed
    Score: 0.002
  284. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol. 2006 Aug; 4(8):988-997.
    View in: PubMed
    Score: 0.002
  285. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005 Dec; 5(12):2913-21.
    View in: PubMed
    Score: 0.002
  286. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005 Oct; 5(10):2433-40.
    View in: PubMed
    Score: 0.002
  287. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol. 2005 Oct; 100(10):2262-73.
    View in: PubMed
    Score: 0.002
  288. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology. 2004 Aug; 127(2):403-11.
    View in: PubMed
    Score: 0.002
  289. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003 Jul; 9(7):672-81.
    View in: PubMed
    Score: 0.001
  290. Uvular necrosis after upper endoscopy: a case report and review of the literature. Endoscopy. 2002 Jul; 34(7):585-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.